Read reviews of all the supplements I've tried over the years here: www.iherb.com/mypage/lotuspocus

Tuesday, 19 February 2013

Calcium supplements may be unhealthy for men

The debate over the safety of calcium supplements has been muddied with the publication of a new analysis showing that a high intake of supplemental calcium increases the risk of cardiovascular disease (CVD) death in men but not in women [1]. Compared with individuals who took no calcium, men who consumed 1000 mg or more of supplemental calcium per day had a significant 20% increased risk of CVD death, a risk that was driven by a significant 19% increased risk of heart-disease death.

For women, however, there was no association between calcium intake and the risk of death.

"We found a significant interaction by sex," write Dr Qian Xiao (National Cancer Institute, Bethesda, MD) and colleagues in their paper, published online February 4, 2013 in JAMA: Internal Medicine. "Elevated CVD mortality with increasing supplemental calcium intake was observed only in men; however, we cannot rule out the possibility that supplemental calcium intake may be associated with cardiovascular mortality in women." The group calls the difference in risk between men and women "intriguing," adding that further studies are needed to determine whether such differential risks are real.

In an editorial [2], Dr Susanna Larsson (Karolinska Institute, Stockholm, Sweden) said the lack of association between calcium supplementation in women is "perplexing," especially given the results of a reanalysis of the WHI study conducted by Dr Mark Bolland (University of Auckland, New Zealand) and colleagues. In the original WHI analysis on the risks associated with calcium use, investigators found no adverse cardiovascular effects in women taking calcium and vitamin D when compared with those not taking the supplements. However, Bolland et al reexamined the WHI data because 54% of women were already taking calcium and vitamin D by personal choice at the start of the WHI study and were not told to stop if they were randomized to placebo. When the data were reanalyzed, the researchers observed a significant association between calcium intake, as well as vitamin D, with the risk of MI.

New Report From NIH Data
The latest report is taken from an analysis of the National Institutes of Health--AARP Diet and Health Study, a study that included 388 229 men and women 50 to 71 years of age from six US states. Individuals self-reported frequency of food intake and portion size during a one-year period and answered questions about the frequency in which they consumed multivitamins, calcium-containing antacids, or calcium supplements alone.

During a mean follow-up of 12 years, there were 7904 and 3874 CVD deaths in men and women, respectively. Dietary intake of calcium was initially associated with total CVD and heart-disease death in men and women, but the association was no longer significant after adjustment for CVD risk factors. Supplemental calcium intake (1000 mg/day vs no calcium supplementation), on the other hand, increased the risk of CVD death and heart-disease death by 20% and 19%, respectively, in men, but there was no association in women. In an analysis that looked only at those taking calcium supplements and not multivitamins, the risk of CVD death and heart-disease death was 24% and 37% higher in men who took 1000 mg/day of calcium compared with those who took no supplements. Again, no association was observed in women who took calcium supplements alone.

There is currently a debate surrounding the benefits and risks of supplemental calcium in men and women. In 2010, researchers published a meta-analysis inBMJ showing that the use of calcium supplements without coadministered vitamin D is associated with an increased risk of MI. This increased risk was later confirmed in an analysis of the patients participating in the European Prospective Investigation into Cancer and Nutrition Study (EPIC).

In the editorial, Larsson concludes that the available evidence is suggestive of an adverse cardiovascular effect with excessive use of calcium supplements. Published as part of JAMA: Internal Medicine's series on "less is more" in medicine, the editorial states that more calcium, which is promoted because of its proposed benefits on bone health, does translate into health benefits. The best source of calcium, says Larsson, remains diet and the consumption of calcium-rich foods such as low-fat dairy, beans, and green leafy vegetables.

Source: http://www.medscape.com/viewarticle/778718

Vitamin D supplements vary in potency

Potency of vitamin D supplements often varies widely from what is listed on the label, according to results from a study of pills from 12 different manufacturers.

The study was authored by Erin S. LeBlanc, MD, MPH, from the Kaiser Permanente Center for Health Research, Portland, Oregon, and colleagues and published online February 11 inJAMA Internal Medicine.

In previous research that focused on vitamin D in menopausal women, Dr. LeBlanc and colleagues found that compounded vitamin D3(cholecalciferol) supplements varied significantly in potency and that only a third of the examined compounded study pills met US Pharmacopeial (USP) Convention standards.

"This variability in compounded cholecalciferol pills led us to additionally investigate over-the-counter (OTC) cholecalciferol pills, in which we also found variability," the authors write.

In this study, the investigators randomly tested the potency of 5 pills from 15 sealed bottles of OTC cholecalciferol dietary supplements (1000 IU, 5000 IU, and 10,000 IU) they purchased at 5 stores in Portland, Oregon.

They found the pills contained from 52% to 135% of the dose listed on the bottles. "When averaged over 5 pills, two-thirds of bottles met USP Convention standards for OTC cholecalciferol solution, which state that contents should be within 90% to 120% of the stated dose," the authors write. In about a quarter of the bottles, all 5 pills met the standards.

The investigators next checked a single pill from 5 bottles with the same lot number and found that potency ranged from 57% to 138% of what was on the label.

They then evaluated a single pill from 5 bottles with different lot numbers. Those pills ranged from 9% to 140% of the stated dose, with mean potencies over the 5 lots ranging from 89% to 105%.

Finally, the researchers analyzed compounded study cholecalciferol pills (1000 IU and 50,000 IU) that had been produced on 3 occasions over the course of several months. Those analyses were done over varied times (0 - 6 months) after compounding. They found that the 50,000-IU tablets contained 52% to 105% of the anticipated dose, whereas the 1000-IU tablets contained 23% to 146% of the expected dose.

"In our test, just over one-half of the OTC pills and only one-third of compounded pills met USP Convention standards," they write.

They say that although lack of accuracy in vitamin D dosing may not cause harm in most people, such deviations could render the supplements less effective. They also point out that variability from pill to pill may undermine the validity of vitamin D trials that use compounded pills to blind participants.

"As more people take vitamin D supplements, it is critical that health care providers and patients understand that cholecalciferol potency may vary widely," they conclude, adding that they agree with calls for increased regulation of dietary supplements.

Source: http://www.medscape.com/viewarticle/779088?nlid=28263_1301&src=wnl_edit_dail&uac=129655SZ

Prenatal folic acid reduces autism risk

More evidence suggests that prenatal folic acid supplementation may lower the risk of developing autism.

A population-based cohort study of almost 85,000 children in Norway showed that those children whose mothers used supplemental folic acid early in pregnancy had 39% lower odds of having autistic disorder than those whose mothers did not use the supplements.

"We were a bit surprised about how large the reduction in risk was and how it was specifically related to folic acid and not to other supplements," Pål Surén, MD, from the Norwegian Institute of Public Health in Oslo, told Medscape Medical News.

"This was also reassuring, because if we had found [the reduction] was associated with other types of supplements as well, it would have been more likely to be explained by healthy behaviors in general, not the supplements per se," he added.

Dr. Surén noted that although more research is needed, "the results support the current recommendations of taking folic acid supplements during pregnancy and emphasize the importance of starting early — preferably before conception."

The study is published in the February issue of JAMA.

Public Health Benefit
Previous research has shown that folic acid supplementation "around the time of conception" can reduce the risk of offspring developing neural tube defects, report the investigators.

"This protective effect has led to mandatory fortification of flour with folic acid in several countries, and it is generally recommended that women planning to become pregnant take a daily supplement...starting 1 month before conception," they write.

"It is not implausible to think that it might also have other beneficial effects, and possibly be protective against other neurodevelopmental disorders, too," said Dr. Surén. "If folic acid truly has a preventive effect against autism in children, it would have great benefits from a public health perspective, because it would be a preventive measure that is cheap and already in use for other purposes."

In a study of more than 700 preschoolers published last year in the American Journal of Clinical Nutrition, investigators from California found that those children whose mothers received at least 600 μg per day of folic acid during their first month of pregnancy had a 38% lower chance of having autism or Asperger syndrome.

For the current analysis, the investigators sought to assess the association between maternal use of folic acid, from 4 weeks before the start of pregnancy to 8 weeks afterwards, and subsequent risk for autism spectrum disorders (ASDs), which include autistic disorder, Asperger syndrome, and pervasive developmental disorder–not otherwise specified (PDD-NOS), in offspring.

The investigators evaluated data on 85,176 children born between 2002 and 2008 who participated in the Norwegian Mother and Child Cohort Study. The mean age of the children at the end of follow-up in March 2012 was 6.4 years.

The Autism Birth Cohort substudy was used to identify cases of ASD in these children.

Inverse Association
Results showed that 270 of the children had been diagnosed with an ASD. Of these, 114 had autistic disorder, 100 had PDD-NOS, and 56 had Asperger syndrome.

Of the children whose mothers took folic acid during early pregnancy, 0.10% had autistic disorder vs 0.21% of those whose mothers did not take the supplements (adjusted odds ratio, 0.61; 95% confidence interval, 0.41 - 0.90).

The inverse association found for folic acid use in early pregnancy and subsequent risk for autistic disorder was not found for folic use during midpregnancy.

Although no association was found between prenatal folic acid supplementation and Asperger syndrome or PDD-NOS, "power was limited," note the investigators.

In addition, further analysis showed no association between risk for an ASD and use of fish oil supplements.

Overall, the main finding does not establish causation between use of folic acid and a lower risk for autistic disorder, write the researchers.

However, it does provide "a rationale for replicating the analyses in other study samples and further investigating genetic factors and other biological mechanisms that may explain the inverse association."

"Reassuring Study"
"It is reassuring that the study...found no association between folic acid supplementation and an increased risk for autistic disorder or ASDs," write Robert J. Berry, MD, and colleagues from the Centers for Disease Control and Prevention in Atlanta, Georgia, in an accompanying editorial.

They note that this has been a hotly debated issue previously. And it is "biologically plausible that folic acid intake might affect numerous conditions positively or negatively depending on timing and dose."

However, past studies have shown strong benefits from folic acid, including a previous report from the Norwegian Mother and Child Cohort Study that showed that supplementation during early pregnancy was associated with a reduced risk for severe language delay in offspring.

The editorialists point out that more research is now needed, including studies that evaluate timing, dose, and intake of supplements, as well as studies that assess children with autism and comorbid conditions.

Nevertheless, "this should ensure that folic acid intake can continue to serve as a tool for the prevention of neural tube birth defects," they write.

"The potential for a nutritional supplement to reduce the risk of autistic disorder is provocative and should be confirmed in other populations."

Source: http://www.medscape.com/viewarticle/779205?nlid=28283_1301&src=wnl_edit_dail

Diet sodas linked to diabetes risk

A new study from France suggests that women who drink large amounts of diet soda are at increased risk for type 2 diabetes. The findings also support the previously documented association between high intake of regular sugar-sweetened beverages and the condition, report Guy Fagherazzi, from the Center for Research in Epidemiology and Population Health, Villejuif, France, and colleagues in a study published online January 30 in the American Journal of Clinical Nutrition.

Prior research into the relationship between diet soda (artificially sweetened beverages) and type 2 diabetes has produced conflicting results, and while the current study does not necessarily imply causation, there are some biologically plausible mechanisms, the researchers suggest.

And given that diet sodas are "considered — and marketed — as healthier than sugar-sweetened beverages," the findings require further investigation, they say. In the meantime, the authors advise that "a precautionary principle could be applied to the promotion of [artificially sweetened beverages]."

Highest Intake of Diet Soda More Than Doubles Diabetes Risk
The data come from a large prospective cohort study of 66,118 women in France investigating links between diet and cancer. There were 1369 new cases of type 2 diabetes diagnosed during the follow-up period from 1993 to 2007.

Based on self-reported dietary consumption, the average intake of regular sodas was 328 mL/week, while for diet sodas it was higher, at 568 mL/week.

The risk for type 2 diabetes was elevated among the women in the highest quartiles for both sugar-sweetened beverages (>359 mL/week) and artificially sweetened beverages (>603 mL/week) compared with women who did not consume those beverages, with hazard ratios of 1.34 and 2.21, respectively, after multivariate adjustment for a variety of covariates (other than body mass index [BMI]).

Strong positive trends in type 2 diabetes risk were observed across quartiles of consumption for both types of beverage (P = .0088 and P < .0001, respectively). Adjustment for BMI did modify the results somewhat, although the associations remained significant for both sugar-sweetened beverages and artificially sweetened beverages.

The authors also conducted sensitivity analyses to test the hypothesis that people who are at risk for type 2 diabetes by virtue of obesity may preferentially drink artificially sweetened beverages, but the results suggest that such a "reverse causation" mechanism is "unlikely," they note.

"Our results — in accordance with a recent joint scientific statement of the AHA and ADA — strongly suggest the need to conduct randomized trials that evaluate metabolic consequences of [artificially sweetened beverage] components, such as artificial sweeteners, to prove a causal link between [artificially sweetened beverage] consumption and type 2 diabetes," the study authors conclude.

Source: http://www.medscape.com/viewarticle/779290?nlid=28284_1301&src=wnl_edit_dail

Diclofenac and cardiovascular risks


The nonsteroidal anti-inflammatory drug (NSAID) diclofenac, a drug that is frequently used for the treatment of pain and inflammation caused by arthritis, is associated with a significantly increased risk of cardiovascular complications and should be removed from essential-medicines lists (EML), according to a new review.

Diclofenac, which is listed on the EML of 74 countries, increased the risk of cardiovascular events between 38% and 63% in different studies. The increased risk with diclofenac was similar to the COX-2 inhibitor rofecoxib (Vioxx, Merck), a drug withdrawn from worldwide markets because of cardiovascular toxicity.

Speaking with heartwire , Dr David Henry(Institute for Clinical Evaluative Sciences, Toronto, ON), who conducted the review along with Dr Patricia McGettigan (London School of Medicine and Dentistry, UK), said that while use of diclofenac in North America is low--the drug has about 5% or 6% of the NSAID market in the US and 17% of the market in Canada--its use is much more common in other non-Western countries.

"The exposure in the North American community is quite low," said Henry, "but the real issue is that it has 30% to 40% of the market share in countries like Vietnam, Pakistan, parts of China, and other countries. These countries are experiencing a real epidemic of cardiovascular disease at the same time these rates are coming down in the West. They are really heavy users of these drugs, in particular diclofenac."

In the review, published online February 12, 2013 inPLoS Medicine, Henry and McGettigan showed that in 15 countries, a list comprising high-, medium-, and low-income countries, diclofenac was the most widely used NSAID. It has a market share roughly equal to the combined market share ofibuprofen, naproxen, andmefenamic acid. The high-risk NSAIDs, diclofenac andetoricoxib, had one-third of the market share across the 15 countries.

Diclofenac, Even in Small Doses, Can Cause Problems
The meta-analysis by McGettigan and Henry also reviewed the relative cardiovascular risks of NSAIDs in observational and randomized studies. Rofecoxib, etoricoxib, and diclofenac were the three agents that were consistently associated with a significantly increased risk when compared with nonuse. Rofecoxib increased the risk of serious cardiovascular events between 27% and 45%, and etoricoxib increased the risk more than twofold compared with nonuse. In two observational studies, diclofenac increased risk of acute MI approximately 38% and 39%, respectively, and increased the risk of cardiovascular events 40%. In one randomized trial, diclofenac was associated with a 63% increased risk of cardiovascular events compared with nonuse.

To heartwire , Henry said the NSAIDs are familiar drugs for physicians and because of such familiarity might be casually prescribed. While the drugs are available over the counter, the cardiovascular risks are associated with the prescription strengths of NSAIDs. For diclofenac, the prescription dose ranges from 100 to 150 mg per day, and this dose is high enough to cause a risk of cardiovascular events, with higher doses associated with even greater risks. With diclofenac, as well as with rofecoxib, there does not appear to be a dose associated with no risk.

"We could find no-risk doses with some of the other drugs, like ibuprofen, naproxen, and celecoxib [Celebrex, Pfizer]," he said. "We could find a dose low enough that didn't increase the risk of heart attacks. The thing with diclofenac is that even in small doses it increases the risk of cardiovascular events. The average dose that is used and marketed is quite high."

Indometacin and meloxicam had a moderately increased risk of cardiovascular events, slightly higher than naproxen, while celecoxib and ibuprofen were associated with an increased risk of cardiovascular toxicity when used at high doses in clinical trials but not in lower doses available over the counter.

An Underappreciated Problem
Dr Gabriel Steg (Centre Hospitalier Bichaut-Claude Bernard, Paris, France), who was not affiliated with the analysis, told heartwire that the cardiovascular risks associated with NSAIDs are an underappreciated problem. He said that most NSAIDs, with the possible exception of naproxen, have some degree of cardiovascular risk associated with them. "I think the converging data from multiple sources indicates that, particularly in patients who are known to have cardiac disease, we should refrain from the chronic use of NSAIDs, if possible," said Steg. "It is conceivable that diclofenac might have a slightly higher risk than the others, but really the issue is the whole class rather than singling out a [particular] agent."

Steg noted that a study published last year inCirculation, reported by heartwire , showed that the use of NSAIDs was associated with a persistently increased risk of coronary events in patients with a previous MI. In more than 43 000 MI patients treated with NSAIDs, their use was associated with a 59% increased risk of death after one year and a 63% increased risk of death after five years of use. In addition, the use of the NSAIDs was associated with an increased risk of coronary death and recurrent MI.

"I think this is a completely underappreciated problem," said Steg. "Most physicians would not be alert to the long-term use of these agents. Many of these agents are over the counter, so physicians are not necessarily aware of their use. Also, they may be used fairly frequently by patients and for very long periods of time. In the elderly, because of bone and joint issues, their use is very common."

To heartwire , Henry said he has written to the World Health Organization(WHO) and has recommended that they advise the EML committees worldwide to preferentially recommend naproxen as the NSAID of choice. He said he does not expect drug regulatory committees, such as the Food and Drug Administration,Health Canada, or the European Medicines Agency (EMA), to withdraw the drugs. In October 2012, the EMA finalized a review that concluded there was a small increase in the risk of cardiovascular side effects with diclofenac compared with other NSAIDs.

"I don't think there is any real new information that would lead them to act, rather than information showing that diclofenac is the most popular drug and it has the same risks as Vioxx," said Henry. "I'm not expecting that change in attitude to suddenly occur. What we'd like to get across to prescribers is to not use diclofenac and to use naproxen. Also, these are not disease-modifying drugs, they're symptom-relieving drugs. We typically tell patients not to stop a medication and to talk to their doctor, but if you have heart disease and are taking diclofenac, do stop the medication and then go talk to your doctor about an alternative."

Source: http://www.medscape.com/viewarticle/779232?nlid=28284_1301&src=wnl_edit_dail

Tuesday, 23 October 2012

Green tea inhibits prostate cancer in clinical trial

The consumption of a lot of green tea might inhibit the growth of prostate cancer tumors by decreasing inflammation and stimulating apoptosis, according to a new study.

After study participants consumed 6 cups of green tea daily for 2 months, serum prostate-specific antigen (PSA) levels were significantly lower than they were at study entry (P < .01), as was the expression of PSA protein in prostate tissue (P = .06). In addition, changes in other biomarkers were observed.

"Our study showed that drinking 6 cups of green tea affected biomarkers in prostate tissue at the time of surgery," said study author Susanne M. Henning, PhD, RD, adjunct professor at the David Geffen School of Medicine at the University of California, Los Angeles. "This research offers new insight into the mechanisms by which green tea consumption may reduce the risk for prostate cancer by opposing processes such as inflammation, which are associated with prostate cancer growth," she explained.

She was speaking at a press briefing held in advance of the 11th Annual American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research, being held in Anaheim, California.

In vitro and other experimental studies have demonstrated the protective effect of green tea against some cancers. Results from epidemiologic studies have been inconclusive about the relation between green tea and prostate cancer, Dr. Henning noted.

However, in an Italian study, green tea catechins reduced the risk for progression to prostate cancer with no significant adverse effects (Cancer Res. 2006;66;1234-1240), she explained.

"Green tea is very high in polyphenols, is convenient, is widely available, and there are already data available from intervention studies," she said.


Changes in PSA and Biomarkers
In this phase 2 study, Dr. Henning and colleagues evaluated the anticarcinogenic effects of green tea in prostate cancer patients prior to surgery.

Of the 67 men who completed the study, 34 were randomized to 6 cups of brewed green tea daily and 33 were randomized to water daily for 3 to 8 weeks before prostatectomy.

Serum PSA concentration, prostate tissue PSA protein level, and prostate concentration of green tea polyphenols and their metabolites were measured. In addition, the effect of green tea on oxidative and inflammatory biomarkers, including protein expression of Ki67 (proliferation), Bcl2, Bax (apoptosis), and nuclear factor kappa B (NFκB) (inflammation), was evaluated.

Bioactive green tea catechins, which include epigallocatechin gallate (EGCG) and its methyl metabolite 4′-O-methyl-EGCG and epicatechin gallate, were detected in the prostate tissue of 31 of 34 men in the green tea group.

In the green tea group, immunostaining showed that intranuclear NFκB significantly declined, but there was no change in cytoplasmic NFκB staining in prostate tumors. The ratio of cytoplasmic staining of proapoptotic Bax to Bcl-2 was significantly higher in the green tea group, but cytoplasmic Bcl2 and Bax staining did not change. There was also no change in nuclear Ki67 staining.

In the control group, there were no changes in PSA levels.

"This is a proof-of-principle study.... The polyphenols are reaching the prostate," Dr. Henning explained. However, in this small, short-term study, no inhibition of tumor growth was seen. "Longer-term studies are needed in the prevention setting," she said.


No Recommendations Just Yet
On the basis of these data, can any recommendations be made about green tea? Not yet, according to Ernest Hawke, MD, vice president and head of the division of cancer prevention and population sciences at the University of Texas M.D. Anderson Cancer Center in Houston.

"This was only a phase 2 trial, so its intentions were pretty limited," he told Medscape Medical News. "It was mainly to figure out if the green tea polyphenols got into the prostate and, if so, what effect they had. That's all that was demonstrated here," he noted.

Dr. Hawk, who was not involved in the study, emphasized that this is a good study because "it defines a dose that can be moved into a definitive larger trial."

The study was conducted in patients with cancer, so it does not establish whether green tea can keep cancer from developing in those at risk, he added.

"To make claims at this point, or to recommend drinking green tea, is the premise for another trial," said Dr. Hawk.


Source: http://www.medscape.com/viewarticle/773011

Wednesday, 12 September 2012

Nonalcoholic red wine reduces blood pressure

Nonalcoholic red wine was associated with a greater reduction in blood pressure than regular red wine in a new study.

The researchers, led by Dr Gemma Chiva-Blanch (University of Barcelona, Spain), conclude that the polyphenols found in red wine are the likely mediators of the blood-pressure reduction and that alcohol appears to weaken their antihypertensive effect.

They suggest that daily consumption of nonalcoholic red wine may be useful for the prevention of mild to moderate hypertension.

For the study, published online in Circulation Research on September 6, 2012, 67 men at high cardiovascular risk were randomized into three four-week treatment periods in a crossover clinical trial. Each participant followed a common background diet and also drank red wine (30 g alcohol/day), the equivalent amount of dealcoholized red wine, or gin (30 g alcohol/day). Blood pressure and plasma nitric-oxide (NO) concentration were measured at baseline and between each intervention. The men were moderate alcohol consumers before the study, but they abstained from drinking any alcohol for a two-week run-in period at the start of the study.

Results showed that both systolic and diastolic blood pressure decreased significantly after the dealcoholized red wine intervention, and these changes correlated with increases in plasma NO. During the red-wine phase, the men had a small reduction in blood pressure and a small increase in NO, while there was no change in blood pressure and a small reduction in NO while drinking gin.

The researchers note that although the blood-pressure reduction associated with nonalcoholic red wine was modest, reductions of this magnitude have been associated with a 14% decrease in coronary heart disease and 20% reduction in stroke risk.


Source: http://www.medscape.com/viewarticle/770508?src=nldne